Topiramate in the Long-Term Treatment of Binge-Eating Disorder Associated with Obesity

McElroy, Susan L.; Shapira, Nathan A.; Arnold, Lesley M.; Keck, Paul E.; Rosenthal, Norman; Wu, Shu‐Chen; Capece, Julie A.; Fazzio, Lydia; Hudson, James I.

doi:10.4088/jcp.v65n1104

Cited by 129 publications

(70 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This observation is in line with observations on topiramate's effects on various addictive and/or compulsive behaviors such as alcohol addiction [6], nicotine addiction [7], sexual compulsive behavior [8], pathological gambling [9] as well as binge-eating disorder [10]. It could be of high interest to investigate the importance of automatic and conditioned processes in overeating in obese patients who probably could have better response to topiramate treatment.…”

supporting

confidence: 87%

Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes

Khazaal

Zullino

2007

Eur J Clin Pharmacol

View full text Add to dashboard Cite

supporting

confidence: 87%

Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes

Khazaal

Zullino

2007

Eur J Clin Pharmacol

View full text Add to dashboard Cite

“…The results have generally been positive in terms of reduction in binge eating episodes and of weight loss, many times involving weight reductions in excess of what is seen with many pharmacological interventions [29][30][31] . Also, trials using zonisamide have been reported, again with positive results on binge eating frequency and again with substantial weight loss .…”

Section: Anti-epilepticsmentioning

confidence: 99%

Biological Therapies for Eating Disorders

Mitchell¹,

Roerig²,

Steffen³

2013

PsycEXTRA Dataset

View full text Add to dashboard Cite

Objective-To provide a comprehensive review of pharmacotherapy and other biological treatments for eating disorders. Method-Literature on this topic was systematically reviewed.Results-The bulimia nervosa literature underscores the utility of antidepressants, particularly SSRIs, in improving the symptoms of the disorder. The literature on binge eating disorder supports efficacy on reduction in binge eating frequency for a variety of compounds. However, such compounds have only modest effects on weight. Certain antiepileptic agents such as topiramate, if tolerated, are probably more useful in terms of weight loss. The number of controlled trials in patients with anorexia nervosa in particular has been quite small, and recent meta-analyses show disappointing results using atypical antipsychotics in anorexia nervosa.Discussion-The pharmacological treatment of eating disorders remains an underdeveloped field although drug therapy clearly plays a role in the treatment of those with bulimia nervosa and binge eating disorder. Other biological therapies have not been adequately studied.Keywords anorexia nervosa; bulimia nervosa; binge eating disorder; pharmacotherapy; drug treatmentThe purpose of this review is to briefly summarize the extant literature on the biological therapies for bulimia nervosa, binge eating disorder and anorexia nervosa. Several other recent reviews have also summarized the literature in this area and may be of interest to readers 1,2 . Pharmacotherapy of Bulimia NervosaSeveral important issues are involved in considering pharmacotherapy for bulimia nervosa (BN). First, as will be seen, the evidence in this area is limited. Many of the reports in the The most frequently studied group of agents are the SSRI antidepressants (fluoxetine -twelve trials, fluvoxamine -three trials, sertraline -one trial and citalopram -one trial) followed by the tricyclic antidepressants (TCAs: desipramine -four trials, imipramine -one trial, and amitriptyline -one trial). Two trials of reversible monoamine oxidase-A inhibitors (MAOI-A) have been reported (brofaromine and moclobemide). Lastly, the serotonin-2 receptor antagonist trazodone (in two trials) has been investigated, as has the serotonin and dopamine reuptake inhibitor bupropion (in one trial). It is important to note that bupropion is contraindicated for the treatment of BN and AN due to its seizure risk. Non-antidepressants have included the serotonin-3 receptor antagonist, ondansetron (one trial), the anticonvulsant topiramate (two trials), the serotonin augmenting agent fenfluramine, which is no longer on the market (one trial), and the androgen antagonist flutamide which was studied in combination with citalopram (see Table 1). Unfortunately, rates of achieving complete remission (abstinence from binge eating and purging) are often not reported. HHS Public Access Controlled TrialsTwenty nine double-blind, placebo controlled trials were reviewed and the type of drug, level of response and abstinence rates are summarized in Table 1. Twelve of the ...

show abstract

“…The 35 subjects who completed this trial were given the opportunity to participate in an open-label extension. The topiramate-treated subjects continued to maintain improvement in binge-eating symptoms and weight (McElroy et al, 2004b). …”

Section: Special Situationsmentioning

confidence: 88%